Special Issue "Oncology in the Era of SARS-CoV-2"
Deadline for manuscript submissions: 31 August 2022 | Viewed by 3942
Interests: SARS-CoV-2; COVID-19; vaccine; mRNA; cancer
Since November 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has resulted in more than 250 million confirmed cases and 5 million deaths worldwide, disrupting all aspects of human society, including patient care. While patients with cancer appear more vulnerable to suffering from complications of SARS-CoV-2 infection, social distancing, lockdown measures as well as the impendence of overhwelmed healthcare systems have severly affected decision-making processes of medical oncologists.
This Special Issue will focus on the impact of the SARS-CoV-2 pandemic in the care of patients with cancer covering aspects such as the epidemiology & management of SARS-CoV-2 infection in patients with malignancy, delayed diagnosis and management of the underlying malignancy, caveats in the design and conduct of clinical trials, running guidelines regarding the vaccination of patients with cancer, mRNA technology and its applications in cancer therapy and the application of the SARS-CoV-2 expertise in the development of novel antineoplastic drugs. Original research articles and reviews are welcome.
We look forward to receiving your contributions.
Prof. Dr. Konstantinos Syrigos
Dr. Ioannis Vathiotis
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.